Business Context and Reporting Period
This Form 8-K is a current report filed by Minerva Neurosciences, Inc. on September 14, 2024. The filing addresses Item 8.01 (Other Events) regarding the scheduling of the Company's 2024 Annual Meeting of Stockholders.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is administrative in nature and does not contain financial performance data.
Material Changes
The Board of Directors set the date for the 2024 Annual Meeting for December 5, 2024. This date is more than 30 days before or after the one-year anniversary of the 2023 Annual Meeting, triggering specific notice requirements under the Company's Bylaws.
Guidance, Outlook, and Management Commentary
- Stockholder Proposals: Proposals intended for inclusion in the proxy statement under Rule 14a-8 must be received by the close of business on October 1, 2024.
- Director Nominations and Business: Stockholders wishing to bring business before the meeting or nominate directors must provide notice by the close of business on October 1, 2024.
- Submission Details: All notices and proposals must conform to the Bylaws and applicable laws and be directed to the Company Secretary at 1500 District Avenue, Burlington, Massachusetts 01803.
Key Facts for Investor Verification
- Annual Meeting Date: December 5, 2024.
- Deadline for Stockholder Proposals and Director Nominations: October 1, 2024.
- Trading Symbol: NERV (Nasdaq Capital Market).
- Reporting Officer: Frederick Ahlholm, Chief Financial Officer.